{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema:tarceva:1 retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Aema%3Atarceva%3A1",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001565,
    "timestamp_received": "2026-11-09T16:13:54.181469Z",
    "timestamp_returned": "2026-11-09T16:13:54.183034Z",
    "trace_id": "1160ea2e-1e56-4e5e-85c0-b7c154fee695"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:ema:tarceva:1",
      "type": "Indication",
      "description": "Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2016-01-25:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2016-01-25",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:tarceva",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tarceva (erlotinib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Roche Registration GmbH.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tarceva",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "erlotinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2009-07-14",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2023-05-16",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The European Medicines Agency (EMA) has authorized erlotinib for switch maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating variants and stable disease after first-line chemotherapy. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.",
          "description": "The description text for all Statements derived from this Indication."
        }
      ]
    }
  ]
}